Stock listing
Dusseldorf:ABL Abbott Laboratories Aktie
German listing (Dusseldorf) of Abbott Laboratories · home listing NYSE:ABT
Follow Abbott Laboratories into a list and get an email when it puts out news.
Share price · DUS:ABL
€94.36 EUR -0.04 (-0.0%)
Close on Nov 20, 2026
- Day range
- €94.36 – €95.24 EURNov 20, 2026
- 52-week range
- €69.33 – €112.46 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €267 EURMedian day 0 shares · 52 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:ABT · Home | $103.00 USD | -1.48 (-1.4%) | 7,292,834 | $104.32 | $105.50 | $102.80 | $104.48 | Close on Nov 20, 2026 |
| Xetra:ABL | €94.94 EUR | -0.62 (-0.6%) | 801 | €95.02 | €95.90 | €94.48 | €95.56 | Close on Nov 20, 2026 |
| BMV:ABT | $1,984.87 MXN | -5.13 (-0.3%) | 26 | $1,975.00 | $1,984.87 | $1,975.00 | $1,990.00 | Close on Nov 19, 2026 |
| B3:ABTT34 | 51.40 BRL | +0.79 (+1.6%) | 105 | 51.40 | 51.40 | 51.40 | 50.61 | Close on Nov 19, 2026 |
| Cboe Canada:ABT | $17.93 CAD | -0.25 (-1.4%) | 800 | $18.06 | $18.06 | $17.93 | $18.18 | Close on Nov 20, 2026 |
| Stuttgart:ABL | €101.15 EUR | -1.80 (-1.7%) | 567 | €102.45 | €104.15 | €100.35 | €102.95 | Close on Nov 5, 2026 |
| Frankfurt:ABL | €95.66 EUR | +0.32 (+0.3%) | 113 | €94.80 | €95.94 | €94.80 | €95.34 | Close on Nov 20, 2026 |
| LSE:0Q15 | $104.06 USD | +0.29 (+0.3%) | 19,611 | $103.72 | $105.59 | $103.16 | $103.77 | Close on Nov 20, 2026 |
| Munich:ABL | €94.91 EUR | -0.09 (-0.1%) | — | €94.91 | €94.91 | €94.91 | €95.00 | Close on Nov 20, 2026 |
| Hamburg:ABL | €94.84 EUR | -0.26 (-0.3%) | — | €94.58 | €95.08 | €94.54 | €95.10 | Close on Nov 20, 2026 |
| Dusseldorf:ABL | €94.36 EUR | -0.04 (0.0%) | — | €94.46 | €95.24 | €94.36 | €94.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · DUS:ABL · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €99.68 | -1.433 | -1.4% | €100.10 | €100.16 | €98.99 | 34 | |
| €101.11 | -0.435 | -0.4% | €101.81 | €104.10 | €99.53 | 0 | |
| €101.55 | +3.532 | +3.6% | €97.74 | €101.96 | €97.64 | 0 | |
| €98.02 | +0.07 | +0.1% | €98.80 | €98.97 | €97.15 | 0 | |
| €97.95 | +3.559 | +3.8% | €94.56 | €98.37 | €94.27 | 0 | |
| €94.39 | +1.152 | +1.2% | €94.21 | €95.52 | €94.16 | 0 | |
| €93.23 | +1.266 | +1.4% | €92.93 | €93.93 | €92.62 | 0 | |
| €91.97 | -0.287 | -0.3% | €91.97 | €91.97 | €91.95 | 0 | |
| €92.26 | +0.206 | +0.2% | €93.05 | €93.78 | €91.50 | 0 | |
| €92.05 | +0.51 | +0.6% | €92.35 | €94.39 | €91.75 | 0 | |
| €91.54 | +0.483 | +0.5% | €91.08 | €91.70 | €90.90 | 0 | |
| €91.06 | +2.761 | +3.1% | €88.68 | €91.52 | €88.30 | 0 | |
| €88.30 | -3.216 | -3.5% | €90.52 | €91.22 | €88.26 | 0 | |
| €91.51 | -0.518 | -0.6% | €92.85 | €93.20 | €91.49 | 0 | |
| €92.03 | -0.419 | -0.5% | €92.41 | €93.07 | €91.48 | 60 | |
| €92.45 | -0.99 | -1.1% | €93.36 | €93.37 | €91.97 | 0 | |
| €93.44 | +0.909 | +1.0% | €92.22 | €93.74 | €91.54 | 0 | |
| €92.53 | +1.079 | +1.2% | €91.54 | €92.55 | €91.28 | 0 | |
| €91.45 | +1.279 | +1.4% | €91.71 | €92.85 | €90.74 | 0 | |
| €90.17 | +1.959 | +2.2% | €89.49 | €90.54 | €89.37 | 0 | |
| €88.21 | +0.504 | +0.6% | €87.98 | €88.87 | €86.89 | 0 | |
| €87.71 | -0.227 | -0.3% | €87.92 | €87.92 | €86.20 | 0 | |
| €87.94 | +0.041 | 0.0% | €87.98 | €88.11 | €87.94 | 0 | |
| €87.89 | -0.531 | -0.6% | €89.08 | €89.12 | €87.73 | 0 | |
| €88.43 | +2.737 | +3.2% | €86.63 | €88.70 | €85.80 | 0 | |
| €85.69 | -0.331 | -0.4% | €86.31 | €87.13 | €85.69 | 0 | |
| €86.02 | -2.387 | -2.7% | €86.04 | €87.33 | €85.94 | 0 | |
| €88.41 | +0.294 | +0.3% | €88.90 | €89.30 | €88.24 | 0 | |
| €88.11 | -1.153 | -1.3% | €88.14 | €88.52 | €87.62 | 15 | |
| €89.27 | +0.83 | +0.9% | €89.41 | €89.61 | €88.94 | 0 | |
| €88.44 | -1.603 | -1.8% | €88.44 | €88.87 | €88.29 | 15 | |
| €90.04 | -0.389 | -0.4% | €91.28 | €91.28 | €89.45 | 0 | |
| €90.43 | -0.081 | -0.1% | €90.89 | €91.50 | €90.28 | 0 | |
| €90.51 | +0.931 | +1.0% | €90.07 | €90.55 | €89.98 | 0 | |
| €89.58 | -0.073 | -0.1% | €89.77 | €89.78 | €88.48 | 0 | |
| €89.65 | +1.554 | +1.8% | €89.42 | €89.79 | €88.83 | 0 | |
| €88.10 | -0.236 | -0.3% | €88.65 | €89.61 | €86.81 | 0 | |
| €88.33 | -0.14 | -0.2% | €87.32 | €88.39 | €87.19 | 0 | |
| €88.47 | -0.287 | -0.3% | €89.55 | €89.55 | €88.00 | 0 | |
| €88.76 | +0.302 | +0.3% | €88.81 | €89.16 | €88.76 | 0 | |
| €88.46 | -0.895 | -1.0% | €88.72 | €89.43 | €87.97 | 0 | |
| €89.35 | -1.878 | -2.1% | €89.81 | €90.04 | €89.23 | 0 | |
| €91.23 | +0.912 | +1.0% | €91.33 | €91.47 | €90.86 | 0 | |
| €90.32 | -1.202 | -1.3% | €91.32 | €91.33 | €90.16 | 0 | |
| €91.52 | -3.116 | -3.3% | €92.13 | €92.24 | €91.15 | 40 | |
| €94.64 | +0.906 | +1.0% | €94.03 | €94.72 | €93.76 | 0 | |
| €93.73 | -2.519 | -2.6% | €95.48 | €95.92 | €93.72 | 0 | |
| €96.25 | +1.372 | +1.4% | €93.63 | €96.58 | €93.58 | 0 | |
| €94.88 | -0.838 | -0.9% | €95.20 | €95.20 | €93.47 | 0 | |
| €95.72 | +0.035 | 0.0% | €95.83 | €96.26 | €95.45 | 0 | |
| €95.68 | -0.37 | -0.4% | €95.24 | €95.80 | €94.82 | 0 | |
| €96.05 | -2.032 | -2.1% | €96.61 | €97.11 | €95.39 | 0 | |
| €98.08 | -0.855 | -0.9% | €98.43 | €98.73 | €97.54 | 0 | |
| €98.94 | -1.299 | -1.3% | €99.85 | €100.73 | €98.60 | 0 | |
| €100.24 | +1.24 | +1.3% | €99.67 | €100.58 | €99.47 | 0 | |
| €99.00 | +0.449 | +0.5% | €98.13 | €99.80 | €96.99 | 0 | |
| €98.55 | +1.092 | +1.1% | €98.57 | €98.63 | €97.73 | 0 |
- Ticker
- Dusseldorf:ABL
- Asset type
- Stock
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
Latest earnings call · Oct 21, 2026
Abbott Laboratories (NYSE:ABT) Q3 2026 Earnings Call
Replay and transcript
Latest news
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
Nov 2, 2026
Closed €97.95 (+3.8%) on Nov 2, 2026
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Nov 1, 2026
Closed €97.95 (+3.8%) on Nov 2, 2026
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Oct 29, 2026
Closed €93.23 (+1.4%) on Oct 29, 2026
Abbott Laboratories receives FDA approval for first and only device in the U.S. to treat leaks after heart valve replacement without additional surgery
Oct 28, 2026
Closed €91.97 (-0.3%) on Oct 28, 2026
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Oct 26, 2026
Closed €92.05 (+0.6%) on Oct 26, 2026
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Oct 23, 2026
Closed €91.54 (+0.5%) on Oct 23, 2026
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Oct 21, 2026
Closed €88.30 (-3.5%) on Oct 21, 2026
Abbott Laboratories on 6ix
- News releases
- 83 in the last 12 months · 108 in all · newest Nov 19, 2026 · oldest 2025
- Calls
- 32 calls with a replay · 32 with a transcript · latest Oct 21, 2026
- Decks
- 34 decks · latest Nov 20, 2025
Where Abbott Laboratories is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:ABT · Home listing | NYSE | United States | USD |
| gettex:ABL | gettex | Germany | EUR |
| BCBA:ABT | BCBA | Argentina | ARS |
| Xetra:ABL | Xetra | Germany | EUR |
| TSX:ABT | TSX | Canada | CAD |
| Tradegate:ABL | Tradegate | Germany | EUR |
| BCBA:ABTD | BCBA | Argentina | USD |
| BMV:ABT | BMV | Mexico | MXN |
| LS Exchange:850103 | LS Exchange | Germany | EUR |
| B3:ABTT34 | B3 | Brazil | BRL |
| Cboe Canada:ABT | Cboe Canada | Canada | CAD |
| Stuttgart:ABL | Stuttgart | Germany | EUR |
| BCBA:ABTC | BCBA | Argentina | USD |
| Frankfurt:ABL | Frankfurt | Germany | EUR |
| LSE:0Q15 | LSE | United Kingdom | USD |
| Milan:1ABT | Milan | Italy | EUR |
| Lang & Schwarz:850103 | Lang & Schwarz | Germany | EUR |
| SIX Swiss:ABT | SIX Swiss | Switzerland | CHF |
| BOATS:ABT | BOATS | United States | USD |
| VIE:ABT | Vienna | Austria | EUR |
| BCS:ABTCL | BCS | Chile | CLP |
| BCS:ABT | BCS | Chile | USD |
| Turquoise:ABTN | Turquoise | United Kingdom | USD |
| Munich:ABL | Munich | Germany | EUR |
| Aquis:ABLD | Aquis | United Kingdom | EUR |
| Hamburg:ABL | Hamburg | Germany | EUR |
| Hanover:ABL | Hanover | Germany | EUR |
| BSESOF:ABL | BSESOF | Bulgaria | EUR |
| BX Swiss:ABL | BX Swiss | Switzerland | CHF |
| BCBA:ABTB | BCBA | Argentina | ARS |
| Dusseldorf:ABL · This page | Dusseldorf | Germany | EUR |
| BIVA:ABT | BIVA | Mexico | MXN |
| BCBA:ABTDB | BCBA | Argentina | USD |
| BVL:ABTUS | BVL | Peru | PEN |
| BCBA:ABTCB | BCBA | Argentina | USD |
| Aquis:ABLD | Aquis | United Kingdom | EUR |
| Frankfurt:ABL0 | Frankfurt | Germany | EUR |
| BCBA:ABT.CI | BCBA | Argentina | ARS |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $205.3B USD
- P/E
- 38.0×
- EV/sales
- 4.3×
- EV/EBITDA
- 25.0×
- Price/book
- 3.5×
- Gross margin
- 56.9%
- Operating margin
- 13.8%
- Net margin
- 9.8%
- Debt to equity
- 0.6×
- Beta vs S&P 500
- 0.11
Forecasts
18 strong buy · 5 buy · 5 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 118.91 USD · Analysts' mean
- EPS, year to Dec 2026
- 5.52 · 27 analysts
- Revenue, year to Dec 2026
- 49.95B · 25 analysts
Team and board
| Officer | Role |
|---|---|
| Rahul Singh | AVP |
Events
Calls
| Call | When | Status |
|---|---|---|
| Abbott Laboratories (NYSE:ABT) Q3 2026 Earnings Call | Wed, Oct 21, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q2 2026 Earnings Call | Thu, Jul 16, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q1 2026 Earnings Call | Thu, Apr 16, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call | Thu, Jan 22, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call | Wed, Oct 15, 2025 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call | Thu, Jul 17, 2025 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call | Wed, Apr 16, 2025 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call | Wed, Jan 22, 2025 · 9:30 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q3 2024 Earnings Call | Wed, Oct 16, 2024 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q2 2024 Earnings Call | Thu, Jul 18, 2024 · 9:00 AM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 21, 2026 · Before open | −1.9% |
| Q2 2026 | Jul 16, 2026 · Before open | +10.7% |
| Q1 2026 | Apr 16, 2026 · Before open | −6.0% |
| Q4 2025 | Jan 22, 2026 · Before open | −10.0% |
| Q3 2025 | Oct 15, 2025 · Before open | −2.9% |
| Q2 2025 | Jul 17, 2025 · Before open | −8.5% |
| Q1 2025 | Apr 16, 2025 · Before open | +2.8% |
| Q4 2024 | Jan 22, 2025 · Before open | +0.8% |
| Q3 2024 | Oct 16, 2024 · Before open | +1.5% |
| Q2 2024 | Jul 18, 2024 · Before open | −4.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 17, 2024 · Before open | −3.0% |
| Q4 2023 | Jan 24, 2024 · Before open | −2.8% |
| Q3 2023 | Oct 18, 2023 · Before open | +3.7% |
| Q2 2023 | Jul 20, 2023 · Before open | +4.2% |
| Q1 2023 | Apr 19, 2023 · Before open | +7.8% |
| Q4 2022 | Jan 25, 2023 · Before open | −1.4% |
| Q3 2022 | Oct 19, 2022 · Before open | −6.5% |
| Q2 2022 | Jul 20, 2022 · Before open | −1.6% |
| Q1 2022 | Apr 20, 2022 · Before open | +2.2% |
| Q4 2021 | Jan 26, 2022 · Before open | −2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (November 2025) | Merger or acquisition | 13 slides | Nov 20, 2025 |
| Technical Presentation (October 2025) | Technical | 16 slides | Oct 26, 2025 |
| Investor Presentation (October 2024) | Investor deck | 41 slides | October 2024 |
| Conference Presentation (October 2024) | Conference | 24 slides | October 2024 |
| Technical Presentation (November 2023) | Technical | 8 slides | November 2023 |
| Fact Sheet (October 2023) | Fact sheet | 1 slide | Oct 11, 2023 |
| Investor Presentation (May 2022) | Investor deck | 30 slides | May 2022 |
| Technical Presentation (April 2022) | Technical | 24 slides | April 2022 |
| a:care Congress (November 2021) | Conference | 40 slides | November 2021 |
| Technical Presentation (October 2021) | Technical | 21 slides | October 2021 |
All 34 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B | 34.6B | 31.9B | 30.6B | 27.4B | 20.9B |
| Cost of revenue | 19.3B | 18.7B | 18.0B | 19.1B | 18.5B | 15.0B | 13.2B | 12.7B | 12.4B | 9.09B |
| Gross profit | 25.0B | 23.2B | 22.1B | 24.5B | 24.5B | 19.6B | 18.7B | 17.9B | 15.0B | 11.8B |
| Research and development | 2.94B | 2.84B | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.26B | 1.45B |
| Selling, general and administrative | 12.3B | 11.7B | 10.9B | 11.2B | 11.3B | 9.70B | 9.77B | 9.74B | 9.18B | 6.74B |
| Operating income | 8.05B | 6.83B | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.56B | 3.03B |
| Depreciation and amortization | 1.43B | 1.34B | 1.28B | 1.25B | 1.49B | 1.20B | 1.08B | 1.10B | 1.05B | 803.0M |
| EBITDA | 9.49B | 8.16B | 7.75B | 9.62B | 9.92B | 6.55B | 5.61B | 4.75B | 2.61B | 3.83B |
| Interest expense | 493.0M | 559.0M | 637.0M | 558.0M | 533.0M | 546.0M | 670.0M | 826.0M | 904.0M | 431.0M |
| Income before tax | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B |
| Income tax | 1.94B | -6.39B | 941.0M | 1.37B | 1.14B | 497.0M | 390.0M | 539.0M | 1.88B | 350.0M |
| Net income | 6.52B | 13.4B | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.0M | 1.40B |
| Earnings per share, basic | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 | 2.07 | 1.34 | 0.27 | 0.94 |
| Earnings per share, diluted | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.52B | 7.62B | 6.90B | 9.88B | 9.80B | 6.84B | 3.86B | 3.84B | 9.41B | 18.6B |
| Short-term investments | 417.0M | 351.0M | 383.0M | 288.0M | 450.0M | 310.0M | 280.0M | 242.0M | 203.0M | 155.0M |
| Receivables | 7.93B | 6.92B | 6.57B | 6.22B | 6.49B | 6.41B | 5.42B | 5.18B | 5.25B | 3.25B |
| Inventory | 6.49B | 6.19B | 6.57B | 6.17B | 5.16B | 5.01B | 4.32B | 3.80B | 3.60B | 2.43B |
| Current assets | 26.0B | 23.7B | 22.7B | 25.2B | 24.2B | 20.4B | 15.7B | 14.6B | 20.1B | 26.8B |
| Property, plant and equipment | 11.8B | 10.7B | 10.2B | 9.16B | 8.96B | 9.03B | 8.04B | 7.56B | 7.61B | 5.71B |
| Goodwill | 24.0B | 23.1B | 23.7B | 22.8B | 23.2B | 23.7B | 23.2B | 23.3B | 24.0B | 7.68B |
| Total assets | 86.7B | 81.4B | 73.2B | 74.4B | 75.2B | 72.5B | 67.9B | 67.2B | 76.3B | 52.7B |
| Current liabilities | 16.5B | 14.2B | 13.8B | 15.5B | 13.1B | 11.9B | 10.9B | 9.01B | 8.91B | 6.66B |
| Long-term debt | 9.90B | 12.6B | 13.6B | 14.5B | 17.3B | 18.5B | 16.7B | 19.4B | 27.2B | 20.7B |
| Total debt | 12.9B | 14.1B | 14.7B | 16.8B | 18.1B | 18.7B | 18.1B | 19.6B | 27.9B | 22.0B |
| Shareholders' equity | 52.1B | 47.7B | 38.6B | 36.7B | 35.8B | 32.8B | 31.1B | 30.5B | 30.9B | 20.5B |
| Shares outstanding | 1.73B | 1.74B | 1.74B | 1.73B | 1.74B | 1.74B | 1.76B | 1.77B | 1.76B | 1.76B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9.57B | 8.56B | 7.26B | 9.58B | 10.5B | 7.90B | 6.14B | 6.30B | 5.57B | 3.20B |
| Capital spending | -2.17B | -2.21B | -2.20B | -1.78B | -1.89B | -2.18B | -1.64B | -1.39B | -1.14B | -1.12B |
| Free cash flow | 7.39B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B | 4.50B | 4.91B | 4.43B | 2.08B |
| Cash from investing | -2.42B | -2.34B | -3.13B | -1.74B | -2.01B | -2.21B | -1.81B | -1.36B | -9.62B | -248.0M |
| Cash from financing | -6.31B | -5.40B | -7.09B | -7.64B | -5.49B | -2.78B | -4.29B | -10.4B | -5.28B | 11.1B |
| Dividends paid | -4.12B | -3.84B | -3.56B | -3.31B | -3.20B | -2.56B | -2.27B | -1.97B | -1.85B | -1.54B |
| Share buybacks | -893.0M | -1.29B | -1.23B | -3.79B | -2.30B | -403.0M | -718.0M | -238.0M | -117.0M | -522.0M |
| Change in cash | 906.0M | 720.0M | -2.99B | 83.0M | 2.96B | 2.98B | 16.0M | -5.56B | -9.21B | 13.6B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 21, 2026 | Current report | SEC |
| 8-K · Current report | Oct 21, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 16, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 18, 2026 | Annual report | SEC |
| SD · Specialized disclosure | May 27, 2026 | ESG report | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 27, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Apr 24, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 17, 2026 | Current report | SEC |
| 8-K · Current report | Apr 16, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Mar 13, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 13, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 25, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 23, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Feb 23, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Feb 23, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 20, 2026 | Current report | SEC |
| 10-K · Annual report | Feb 20, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| 8-K · Current report | Nov 20, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 17, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2025 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 20, 2025 | Annual report | SEC |
| SD · Specialized disclosure | May 29, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 1, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Apr 30, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 30, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Apr 16, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 14, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Mar 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 21, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 29, 2025 | Other filings | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Abbott Laboratories’ releases · as of Sep 30, 2026
- Common shares
- 1,731,941,601
- Fully diluted
- 1,731,941,601
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,731,941,601 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 1,731,941,601 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward M Liddy Other companies: AbbVie Inc. (Director · Dec 12, 2012 – Mar 31, 2022 · Past); American International Group, Inc. New (Chairman & CEO, Director · Sep 18, 2008 – Sep 18, 2008 · Past); Boeing Company (the) (Director · Aug 28, 2007 – Apr 1, 2020 · Past); Goldman Sachs Group, Inc. (the) (Director · Dec 15, 2006 – Dec 19, 2007 · Past); Allstate Corporation (the) (Chairman, Director · Feb 21, 2006 – Feb 22, 2008 · Past); 3M Company (Director · Dec 31, 2005 – May 1, 2020 · Past); Kroger Company (the) (Director · Dec 31, 2005 – Dec 31, 2005 · Past) | Director · Jun 11, 2010 – Apr 24, 2020 · Past |
| Jack M Greenberg Other companies: IQVIA Holdings, Inc. (Director · May 8, 2013 – Apr 26, 2018 · Past); Western Union Company (the) (Director · Sep 29, 2009 – Feb 20, 2015 · Past); InnerWorkings Inc (Director · Aug 15, 2006 – Oct 1, 2020 · Past); Allstate Corporation (the) (Director · Feb 23, 2006 – Mar 5, 2015 · Past); First Data Corporation (Director · Feb 8, 2006 – Sep 1, 2006 · Past); Hasbro, Inc. (Director · Dec 30, 2005 – Mar 31, 2015 · Past); ManpowerGroup (Director · Dec 30, 2005 – Jan 1, 2014 · Past) | Director · Apr 28, 2006 – Apr 28, 2006 · Past |
| Glenn F Tilton Other companies: Phillips 66 (Director · Since at least May 1, 2012); AbbVie Inc. (Director · Dec 12, 2012 – May 9, 2025 · Past); Corning Incorporated (Director · Nov 30, 2010 – Feb 1, 2012 · Past); United Airlines Holdings, Inc. (Director · Feb 1, 2006 – Jun 12, 2013 · Past); Txu Corp (Director · Jan 9, 2006 – Jan 9, 2007 · Past); Lincoln National Corporation (Director · Dec 30, 2005 – Mar 31, 2007 · Past) | Director · Apr 27, 2007 – Apr 29, 2022 · Past |
| Kevin T Conroy Other companies: American Exceptionalism Acquisition Corp. A (Director · Since at least Sep 25, 2025); Align Technology, Inc. (Director · Since at least Dec 5, 2023); EXACT Sciences Corporation (President and CEO, Director · Since at least Mar 18, 2009); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Mar 6, 2023 · Past); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Jul 1, 2020 · Past); Epizyme Inc (Director · Feb 6, 2017 – Aug 12, 2022 · Past) | Director · Since at least Apr 24, 2026 |
| Roxanne Austin Other companies: Freshworks Inc. (Director · Since at least Sep 21, 2021); Verizon Communications Inc. (Director · Since at least Oct 2, 2020); CrowdStrike Holdings, Inc. (President, Austin Investment Advisors · Since at least Jun 11, 2019); AbbVie Inc. (President · Since at least Dec 12, 2012); Teledyne Technologies Incorporated (Director · Jan 29, 2006 – Jun 5, 2020 · Past); Target Corporation (Director · Jan 11, 2006 – Jun 2, 2020 · Past) | Director · Apr 28, 2006 – Apr 23, 2021 · Past |
| W James Farrell Other companies: 3M Company (Director · Aug 14, 2006 – May 13, 2014 · Past); Allstate Corporation (the) (Director · Jun 1, 2006 – Dec 7, 2012 · Past); United Airlines Holdings, Inc. (Director · Feb 1, 2006 – Jun 9, 2012 · Past); Illinois Tool Works Inc. (Chairman, Director · Jan 5, 2006 – Apr 21, 2006 · Past); Mondelez International, Inc. (Director · Dec 31, 2005 – Apr 26, 2006 · Past) | Director · Jan 16, 2006 – Apr 29, 2016 · Past |
| William A Osborn Other companies: General Dynamics Corporation (Director · Dec 1, 2009 – Mar 8, 2021 · Past); Caterpillar, Inc. (Director · Jun 14, 2006 – Mar 1, 2021 · Past); Tribune Media Company (Director · May 3, 2006 – Dec 20, 2007 · Past); Northern Trust Corporation (Chairman of the Board, Director · Jan 20, 2006 – Dec 15, 2008 · Past) | Director · Jan 2, 2008 – Apr 29, 2022 · Past |
| William G Dempsey Other companies: Ashland Inc. (Director · Jul 20, 2016 – Dec 30, 2022 · Past); Hill-Rom Holdings Inc (Director · Mar 7, 2014 – Dec 13, 2021 · Past); Hospira Inc (Director · Aug 17, 2011 – Sep 3, 2015 · Past); Landauer Inc (Director · Oct 30, 2008 – Oct 19, 2017 · Past) | Executive Vice President · Dec 31, 2005 – Aug 7, 2007 · Past |
| Carlos Albán Other companies: Solventum Corporation (Director · Since at least Apr 1, 2024); SpringWorks Therapeutics Inc (Director · Since at least Jul 14, 2022); AbbVie Inc. (Vice Chairman · Dec 7, 2012 – Nov 16, 2020 · Past) | Senior Vice President · Oct 15, 2009 – Dec 1, 2012 · Past |
| John G Stratton Other companies: Frontier Communications Parent Inc (Exec. Chairman of the Board, Director · Since at least Apr 30, 2021); General Dynamics Corporation (Director · Since at least Feb 5, 2020); Verizon Communications Inc. (EVP&Pres - Global Operations · Oct 5, 2017 – May 31, 2018 · Past) | Director · Since at least Sep 30, 2017 |
All 74 people
| Person | Seat |
|---|---|
| Michael Dale Other companies: CVRx, Inc. (Chief Executive Officer and President · Since at least Apr 20, 2026); Axogen, Inc. (President, Chief Executive Officer and Board Director · Since at least Aug 9, 2024); Ats Medical Inc (Chief Executive Officer · Jan 10, 2006 – Aug 12, 2010 · Past) | SENIOR VICE PRESIDENT · Nov 11, 2019 – Feb 28, 2023 · Past |
| Michelle Kumbier Other companies: Ryerson Holding Corporation (Director · Since at least Apr 25, 2024); Teledyne Technologies Incorporated (Director · Since at least Oct 20, 2020); Tenneco Inc (Director · Aug 10, 2021 – Nov 17, 2022 · Past) | Director · Since at least Feb 23, 2021 |
| Nancy McKinstry Other companies: Automatic Data Processing, Inc. (Director · Since at least Nov 11, 2026); Mondelez International, Inc. (Director · Since at least May 21, 2025); Accenture plc (Director · Since at least May 15, 2019) | Director · Since at least Apr 26, 2019 |
| Samuel C Scott III Other companies: GCM Grosvenor Inc. (Director · Since at least Nov 17, 2020); Motorola Solutions, Inc. (Director · May 16, 2016 – May 14, 2018 · Past); The Bank of New York Mellon Corporation (Director · Apr 22, 2016 – Feb 11, 2022 · Past) | Director · Apr 29, 2016 – Apr 26, 2019 · Past |
| Thomas C. Freyman Other companies: AbbVie Inc. (Director · Since at least May 8, 2020); Hanger Inc (Director · Nov 14, 2017 – Oct 3, 2022 · Past); Tenneco Inc (Director · Jul 14, 2015 – Nov 17, 2022 · Past) | Executive Vice President · Feb 19, 2016 – Jul 29, 2016 · Past |
| Thomas F Chen Other companies: Stericycle Inc (Director · May 21, 2014 – Nov 4, 2024 · Past); Baxter International Inc. (Director · Jan 25, 2013 – May 3, 2022 · Past); Cyanotech Corporation (Director · Jun 6, 2011 – Aug 27, 2012 · Past) | Senior Vice President · Apr 24, 2006 – May 25, 2010 · Past |
| William D Smithburg Other companies: Niagen Bioscience, Inc. (Director · Jun 6, 2016 – Jun 6, 2016 · Past); Corning Incorporated (Director · Dec 30, 2005 – Mar 30, 2012 · Past); Northern Trust Corporation (Director · Dec 30, 2005 – Apr 20, 2010 · Past) | Director · Dec 31, 2005 – Nov 9, 2010 · Past |
| Andrea F. Wainer Other companies: Neogen Corporation (Director · Since at least May 13, 2025); Analog Devices, Inc. (Director · Since at least Jan 9, 2025) | RETIRED EVP · Jun 3, 2019 – Feb 28, 2025 · Past |
| Daniel J Starks Other companies: Urologix (Director · Aug 22, 2006 – Nov 11, 2008 · Past); St. Jude Medical Inc (Director · Feb 7, 2006 – Jan 4, 2017 · Past) | Director · Since at least Feb 16, 2017 |
| Darren W McDew Other companies: GE Aerospace (Director · Since at least Mar 30, 2023); Parsons Corporation (Director · Since at least Apr 20, 2021) | Director · Since at least Apr 23, 2021 |
| Heather L. Mason Other companies: Immatics N.V. (Non-Executive Director · Since at least Mar 18, 2026); Assertio Holdings, Inc. (Director · Since at least May 19, 2020) | Executive Vice President · May 1, 2008 – Jul 1, 2017 · Past |
| James V Mazzo Other companies: Aerie Pharmaceuticals Inc. (Director · Jun 11, 2014 – Jun 11, 2014 · Past); Microsemi Corporation (Director · Aug 7, 2012 – Feb 11, 2014 · Past) | Senior Vice President · Aug 26, 2010 – Feb 4, 2013 · Past |
| Lisa D Earnhardt Other companies: Nevro Corp (Director · May 21, 2018 – May 21, 2018 · Past); Intersect ENT Inc (Director · Oct 16, 2017 – Jul 24, 2019 · Past) | EVP AND GROUP PRESIDENT · Since at least Jun 10, 2019 |
| Michael Roman Other companies: Waystar Holding Corp. (Director · Since at least Jun 4, 2025); 3M Company (Chairman of the Board, Director · Feb 2, 2016 – Feb 3, 2025 · Past) | Director · Since at least Apr 23, 2021 |
| Rahul Singh Other companies: Dow Inc. (AVP · Since at least May 15, 2026); 3M Company (AVP · Since at least Apr 27, 2026) | AVP · Since at least May 5, 2026 |
| Robert J Alpern Other companies: AbbVie Inc. (Director · Since at least Dec 12, 2012); Tricida Inc (Director · Jun 27, 2018 – Nov 23, 2022 · Past) | Director · Since at least Oct 10, 2008 |
| Roy S Roberts Other companies: AbbVie Inc. (Director · Dec 12, 2012 – May 8, 2015 · Past); Burlington Northern Santa Fe Corp (Director · Dec 30, 2005 – Feb 12, 2010 · Past) | Director · Dec 31, 2005 – Jan 31, 2011 · Past |
| Charles Brynelsen Other companies: Envoy Medical, Inc. (Director · Since at least Sep 29, 2023) | SENIOR VICE PRESIDENT · Feb 16, 2018 – Feb 26, 2021 · Past |
| Edward L Michael Other companies: QuidelOrtho Corporation (Director · Since at least May 27, 2022) | Executive Vice President · Mar 1, 2007 – Feb 29, 2012 · Past |
| Holger A Liepmann Other companies: Verenium Corp (Director · Mar 31, 2013 – Oct 31, 2013 · Past) | Executive Vice President · Jan 31, 2006 – Dec 23, 2010 · Past |
| Jacob A Orville Other companies: EXACT Sciences Corporation (EVP, GM, Screening · Since at least Feb 16, 2021) | Senior Vice President · Since at least Mar 23, 2026 |
| Jeffrey R Binder Other companies: Biomet Inc (President & CEO, Director · Feb 26, 2007 – Feb 26, 2007 · Past) | Senior Vice President · Jan 15, 2006 – Feb 17, 2007 · Past |
| John A McCoy Other companies: Baxalta Inc (SVP and Controller · Jun 30, 2015 – Jun 3, 2016 · Past) | VICE PRESIDENT AND CONTROLLER · Since at least Sep 1, 2023 |
| Michael O'Grady Other companies: Northern Trust Corporation (Chairman and CEO, Director · Since at least Dec 3, 2025) | Director · Since at least Apr 25, 2025 |
| Michael T Rousseau Other companies: St. Jude Medical Inc (Director, President and CEO, Director · Feb 3, 2006 – Jan 4, 2017 · Past) | Pres., Cardiovas. & Neuromod. · Jan 4, 2017 – Jul 7, 2017 · Past |
| Murthy V Simhambhatla Other companies: Evolus, Inc. Common Stock (See Remarks, Director · Feb 7, 2018 – Feb 7, 2018 · Past) | Senior Vice President · Jan 1, 2013 – Feb 27, 2015 · Past |
| Richard A Gonzalez Other companies: AbbVie Inc. (Director · Dec 7, 2012 – Mar 31, 2025 · Past) | Executive Vice President · Nov 17, 2005 – Apr 6, 2012 · Past |
| Sally E Blount Other companies: Ulta Beauty, Inc. (Director · Dec 6, 2017 – Jun 2, 2021 · Past) | Director · Since at least Dec 9, 2011 |
| A David Forrest | Senior Vice President · Sep 17, 2010 – Sep 17, 2013 · Past |
| Alejandro D Wellisch | SENIOR VICE PRESIDENT · Oct 1, 2017 – Feb 28, 2023 · Past |
| Andrew H Lane | EXECUTIVE VICE PRESIDENT · Feb 16, 2018 – Nov 15, 2021 · Past |
| Charles D Foltz | Senior Vice President · Apr 1, 2013 – Apr 1, 2015 · Past |
| Christopher J Calamari | SENIOR VICE PRESIDENT · Jul 1, 2021 – Feb 28, 2023 · Past |
| Christopher J Scoggins | EXECUTIVE VICE PRESIDENT · Since at least Apr 1, 2019 |
| Claire Babineaux-Fontenot | Director · Since at least Apr 25, 2025 |
| Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT · Since at least Sep 26, 2014 |
| Deepak S Nath | Senior Vice President · Apr 1, 2015 – Apr 28, 2017 · Past |
| Elizabeth C Cushman | EVP, GC AND SECRETARY · Since at least Jun 27, 2025 |
| Eric Shroff | Senior Vice President · Since at least Mar 1, 2025 |
| Fernando Mateus | SENIOR VICE PRESIDENT · Dec 1, 2021 – Feb 28, 2023 · Past |
| Georges H DeVos | Senior Vice President · Jul 1, 2013 – Feb 27, 2015 · Past |
| Hubert L Allen | EXECUTIVE VICE PRESIDENT, GC · Feb 1, 2021 – Feb 28, 2025 · Past |
| Jaime Contreras | Senior Vice President · Sep 16, 2013 – Apr 21, 2020 · Past |
| Jared Watkin | SENIOR VICE PRESIDENT · Jun 15, 2015 – Feb 28, 2023 · Past |
| Jean-Yves Pavee | Senior Vice President · Jul 1, 2013 – Jul 1, 2016 · Past |
| John F Ginascol | EXECUTIVE VICE PRESIDENT · Jun 3, 2019 – Feb 28, 2023 · Past |
| John M Capek | EXECUTIVE VICE PRESIDENT · Feb 17, 2023 – Feb 28, 2023 · Past |
| Joseph J Manning | EXECUTIVE VICE PRESIDENT · Jan 16, 2017 – Feb 28, 2023 · Past |
| Julie L Tyler | SENIOR VICE PRESIDENT · Jul 1, 2021 – Feb 28, 2023 · Past |
| Louis H Morrone | EXECUTIVE VICE PRESIDENT · Since at least Jul 1, 2021 |
| Mary K Moreland | EXECUTIVE VICE PRESIDENT · Since at least Feb 16, 2021 |
| Michael J Pederson | SENIOR VICE PRESIDENT · Jul 21, 2017 – Feb 28, 2023 · Past |
| Michael J Warmuth | Executive Vice President · Dec 15, 2008 – Feb 28, 2017 · Past |
| Nita Ahuja | Director · Since at least Dec 12, 2025 |
| Patricia Paola Gonzalez | Director · Since at least Aug 30, 2021 |
| Paul K Magill | Senior Vice President · Nov 1, 2012 – Feb 15, 2013 · Past |
| Philip P Boudreau | EVP AND CFO · Since at least Aug 8, 2025 |
| Randel William Woodgrift | SENIOR VICE PRESIDENT · Apr 1, 2019 – Feb 28, 2023 · Past |
| Robert B Ford | CHAIRMAN AND CEO, Director · Since at least Jun 6, 2019 |
| Robert E Funck Jr | EXECUTIVE VICE PRESIDENT · Mar 1, 2013 – May 10, 2024 · Past |
| Roger Bird | SENIOR VICE PRESIDENT · Mar 1, 2015 – Apr 27, 2021 · Past |
| Sean Shrimpton | Senior Vice President · May 15, 2017 – Dec 31, 2018 · Past |
| Sharon J Bracken | Senior Vice President · Jul 10, 2017 – Mar 31, 2019 · Past |
| Stephen R Fussell | Executive Vice President · Jan 30, 2018 – Apr 23, 2019 · Past |
Log in to ask 6ix AI your own questions about Abbott Laboratories.